Posted On: 03/30/2015 5:20:13 PM
Post# of 273309
Actavis Inc (ACT) 304.76 $ACT
Mallinckrodt Reports Acthar Gel Data on Nephrotic Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 38 mins ago
Mallinckrodt plc (MNK) reported two separate presentations by independent physicians on patients treated with H.P. Acthar Gel.
MNK: 130.13 (+0.52), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40), SLXP: 172.65 (+0.05)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 30, 9:19AM CDT
OCR: 77.85 (+1.05), ELLI: 55.03 (+0.41), JCOM: 68.40 (+0.93), CAH: 90.80 (+0.71), AET: 108.57 (+1.17), BABY: 39.68 (+0.55), DFT: 33.28 (+0.92), NLNK: 56.40 (+4.14), HSIC: 140.84 (+2.04), MNK: 130.13 (+0.52), CAVM: 72.75 (+0.81), HAS: 62.57 (+1.54), BCR: 169.37 (+1.66), MCHP: 49.89 (+0.68), MYL: 60.00 (-1.63), NXPI: 102.43 (+2.51), EV: 41.83 (+0.59), NVDA: 21.47 (+0.09), LVLT: 54.47 (+0.52), CBRL: 152.79 (+1.71), MTSI: 37.00 (+1.19), AZO: 689.38 (+8.04), EQIX: 234.22 (+4.49), IRWD: 16.53 (+0.86), AVB: 176.15 (+2.03), KNX: 32.35 (+0.70), HAE: 44.97 (+0.76), FSL: 41.48 (+0.77), FHN: 14.37 (+0.31), BDX: 145.64 (+1.05), ACT: 304.76 (+1.20), F: 16.16 (+0.18), AON: 98.10 (+2.23), NUVA: 46.40 (+1.80), CDW: 37.75 (-0.07), ANTM: 156.85 (+0.58), APH: 58.77 (+1.13), INFA: 44.39 (+0.43), EXAM: 41.61 (-0.25), LII: 111.37 (+0.85), BJRI: 51.24 (+0.31), BDN: 16.16 (+0.27), DPZ: 102.55 (+1.50), FL: 63.61 (+1.76), DLX: 68.78 (+1.85), ABT: 47.08 (+0.30), BMR: 22.76 (+0.41), HCN: 78.71 (+0.93), DIOD: 29.25 (+1.29), LEG: 45.99 (+0.63), DIS: 106.12 (+0.64), GLW: 23.24 (+0.50), MAR: 81.50 (+0.68), ASML: 103.12 (+1.26), IMAX: 34.00 (+0.29), CNC: 71.23 (+2.01), CTAS: 82.74 (+0.36), FLO: 22.78 (+0.34), CRM: 66.85 (+0.30)
Teva Phamaceutical Industries Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Mon Mar 30, 7:50AM CDT
KMI: 42.07 (+0.80), ACT: 304.76 (+1.20), JAH: 53.45 (+0.86), WBK: 30.26 (-0.09), CNQ: 30.83 (+0.10), DISH: 70.78 (+0.15), SU: 29.20 (+0.09), HCA: 76.17 (+0.10), GS: 191.02 (+2.96), JPM: 60.96 (+1.41), BAX: 68.76 (+0.21), RY: 59.35 (-0.30), TEVA: 62.52 (+0.54), SNY: 50.24 (+0.27), Y: 490.00 (+6.47), ECL: 114.79 (+0.55)
Which 4 Big Drugmakers Have Rising Estimates?
at Investor's Business Daily - Fri Mar 27, 12:16PM CDT
Drugmaker shares have been plunging this week, but the recent sell-off shouldn't necessarily be taken as an indicator that these stocks are doing poorly. Today's Screen of the Day features Leaders with Rising Estimates -- stocks with rising earnings...
LCI: 67.86 (+2.35), BIIB: 431.62 (+1.75), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40)
Has Orexigen Delivered A Death Knell To Vivus?
Spencer Osborne - at Seeking Alpha - Fri Mar 27, 9:37AM CDT
OREX: 7.75 (+0.21), ACT: 304.76 (+1.20), VVUS: 2.52 (-0.05)
Leon Cooperman's Firm Is Under Investigation and This Is Where He Is Investing His Money
at The Street - Fri Mar 27, 7:23AM CDT
Investigators looking into Leon Cooperman's Omega Advisors have quite a bit to wade through -- the billionaire has upwards of 90 securities in his public equity portfolio alone.
ACT: 304.76 (+1.20), RIG: 14.71 (+0.22), ATLS: 6.26 (+0.08), S: 4.75 (+0.03), HAL: 43.82 (+0.56), NAO: 9.10 (+0.25), LINE: 11.30 (-0.27), AIG: 54.68 (+0.65), SIRI: 3.87 (+0.02), NAVI: 20.08 (-0.08), APC: 83.85 (+1.66)
Top Large Cap Stocks That Investors Can Buy Now
Todd Campbell - at Seeking Alpha - Thu Mar 26, 2:20AM CDT
ASH: 128.71 (+1.18), OCR: 77.85 (+1.05), ACT: 304.76 (+1.20), BDX: 145.64 (+1.05), F: 16.16 (+0.18), CAH: 90.80 (+0.71), PSA: 199.19 (+1.71), SLG: 129.55 (+1.81), AON: 98.10 (+2.23), AET: 108.57 (+1.17), VTR: 73.65 (+1.33), CDW: 37.75 (-0.07), ANTM: 156.85 (+0.58), APH: 58.77 (+1.13), Q: 68.00 (+0.74), FL: 63.61 (+1.76), HSIC: 140.84 (+2.04), APD: 153.80 (+1.05), HAS: 62.57 (+1.54), ABT: 47.08 (+0.30), BCR: 169.37 (+1.66), HCN: 78.71 (+0.93), ORLY: 219.38 (+3.96), MCHP: 49.89 (+0.68), MYL: 60.00 (-1.63), DIS: 106.12 (+0.64), NXPI: 102.43 (+2.51), GLW: 23.24 (+0.50), MAR: 81.50 (+0.68), BA: 152.70 (+3.85), WAT: 124.94 (+0.83), ASML: 103.12 (+1.26), NVDA: 21.47 (+0.09), LVLT: 54.47 (+0.52), CTAS: 82.74 (+0.36), PLL: 101.63 (+1.14), AZO: 689.38 (+8.04), EQIX: 234.22 (+4.49), AVB: 176.15 (+2.03), SUNE: 24.19 (-0.17), TDG: 219.83 (+1.96), BEAV: 63.99 (+1.85), SHW: 284.24 (+2.56), FSL: 41.48 (+0.77), CRM: 66.85 (+0.30)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 157.27 (+1.47), BIIB: 431.62 (+1.75), IHF: 134.13 (+1.61), ACT: 304.76 (+1.20), VRX: 201.38 (+3.54), MRK: 58.34 (+0.59), SHPG: 241.98 (+1.01), PFE: 35.00 (+0.47), PTH: 61.68 (+1.07), XHS: 124.93 (+0.87), SLXP: 172.65 (+0.05), ABBV: 58.24 (+0.59)
Technical Analysis on Pharma Equities -- Zoetis, Horizon Pharma, Valeant Pharma Intl., Actavis, and Medicines
PR Newswire - Wed Mar 25, 8:57AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ZTS: 46.92 (+0.70), ACT: 304.76 (+1.20), VRX: 201.38 (+3.54), MDCO: 28.36 (-0.24), HZNP: 25.77 (+3.96), VRX.TO: 256.67 (+9.24)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ACT: 304.76 (+1.20), AIRM: 46.75 (-0.27), CENT: 10.08 (+0.04), AEZS: 0.53 (unch), AAPL: 126.37 (+3.12)
Trevena's Q4 2014 Results Conference Call - What We Learned
Scrying Biotech - at Seeking Alpha - Mon Mar 23, 12:14PM CDT
TRVN: 6.64 (-0.33), ACT: 304.76 (+1.20)
5 Rocket Stocks That Are Ready for Blastoff
at The Street - Mon Mar 23, 7:21AM CDT
These stocks have both short-term gain catalysts and longer-term growth potential.
ACT: 304.76 (+1.20), RAX: 52.38 (+0.42), ADI: 64.81 (+5.97), FL: 63.61 (+1.76), HOT: 84.33 (-0.90)
Vivus: Qsymia Sales Slip, Company Needs To Shift Into Gear
Spencer Osborne - at Seeking Alpha - Mon Mar 23, 5:51AM CDT
OREX: 7.75 (+0.21), ACT: 304.76 (+1.20), VVUS: 2.52 (-0.05), ARNA: 4.48 (+0.15)
Drug Stocks Are Hot: Meet The 5 Best On The IBD 50
at Investor's Business Daily - Sat Mar 21, 7:02AM CDT
Today's IBD 50 roundup features five top drugmakers that have been making headlines. Even though they've all now extended past buying range, they may yet form new bases, and investors won't want to be late to blink-and-you'll-miss-it key price...
ENDP: 91.53 (+1.49), BIIB: 431.62 (+1.75), VRX: 201.38 (+3.54), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40), SLXP: 172.65 (+0.05)
Is There Any Potential Left In Horizon Pharma Stock?
Max Grigoryev - at Seeking Alpha - Fri Mar 20, 1:55PM CDT
JNJ: 101.55 (+1.21), ACT: 304.76 (+1.20), PFE: 35.00 (+0.47), AZN: 69.94 (-0.13), HZNP: 25.77 (+3.96), MYL: 60.00 (-1.63), TEVA: 62.52 (+0.54)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 431.62 (+1.75), ACT: 304.76 (+1.20), OVAS: 38.18 (-5.29), RGLS: 17.26 (+0.44), CTIC: 1.87 (+0.06), CELG: 120.02 (+1.34), BLCM: 22.65 (+0.19), GILD: 100.69 (-0.31), KITE: 59.98 (+0.20), MRK: 58.34 (+0.59), RCPT: 160.05 (+12.62), JUNO: 60.66 (+4.06), NVS: 101.31 (+0.91)
AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 3:20PM CDT
AstraZeneca's (AZN) respiratory candidate, PT003, being developed for the treatment of chronic obstructive pulmonary disease, is found positive in late-stage PINNACLE studies.
ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40), AZN: 69.94 (-0.13), GSK: 47.20 (+0.18)
Global Parenteral Nutrition Industry
PR Newswire - Wed Mar 18, 3:51PM CDT
This report analyzes the worldwide markets for Parenteral Nutrition in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -
ACT: 304.76 (+1.20)
Actavis' pending acquisition of Allergan approved by European Commission
M2 - Wed Mar 18, 6:41AM CDT
Pharmaceutical company Actavis (NYSE:ACT) reported on Tuesday that it has received clearance from the European Commission for its pending acquisition of Allergan (NYSE:AGN).
AGN: 240.22 (+2.88), ACT: 304.76 (+1.20)
Mallinckrodt Reports Acthar Gel Data on Nephrotic Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 38 mins ago
Mallinckrodt plc (MNK) reported two separate presentations by independent physicians on patients treated with H.P. Acthar Gel.
MNK: 130.13 (+0.52), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40), SLXP: 172.65 (+0.05)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 30, 9:19AM CDT
OCR: 77.85 (+1.05), ELLI: 55.03 (+0.41), JCOM: 68.40 (+0.93), CAH: 90.80 (+0.71), AET: 108.57 (+1.17), BABY: 39.68 (+0.55), DFT: 33.28 (+0.92), NLNK: 56.40 (+4.14), HSIC: 140.84 (+2.04), MNK: 130.13 (+0.52), CAVM: 72.75 (+0.81), HAS: 62.57 (+1.54), BCR: 169.37 (+1.66), MCHP: 49.89 (+0.68), MYL: 60.00 (-1.63), NXPI: 102.43 (+2.51), EV: 41.83 (+0.59), NVDA: 21.47 (+0.09), LVLT: 54.47 (+0.52), CBRL: 152.79 (+1.71), MTSI: 37.00 (+1.19), AZO: 689.38 (+8.04), EQIX: 234.22 (+4.49), IRWD: 16.53 (+0.86), AVB: 176.15 (+2.03), KNX: 32.35 (+0.70), HAE: 44.97 (+0.76), FSL: 41.48 (+0.77), FHN: 14.37 (+0.31), BDX: 145.64 (+1.05), ACT: 304.76 (+1.20), F: 16.16 (+0.18), AON: 98.10 (+2.23), NUVA: 46.40 (+1.80), CDW: 37.75 (-0.07), ANTM: 156.85 (+0.58), APH: 58.77 (+1.13), INFA: 44.39 (+0.43), EXAM: 41.61 (-0.25), LII: 111.37 (+0.85), BJRI: 51.24 (+0.31), BDN: 16.16 (+0.27), DPZ: 102.55 (+1.50), FL: 63.61 (+1.76), DLX: 68.78 (+1.85), ABT: 47.08 (+0.30), BMR: 22.76 (+0.41), HCN: 78.71 (+0.93), DIOD: 29.25 (+1.29), LEG: 45.99 (+0.63), DIS: 106.12 (+0.64), GLW: 23.24 (+0.50), MAR: 81.50 (+0.68), ASML: 103.12 (+1.26), IMAX: 34.00 (+0.29), CNC: 71.23 (+2.01), CTAS: 82.74 (+0.36), FLO: 22.78 (+0.34), CRM: 66.85 (+0.30)
Teva Phamaceutical Industries Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Mon Mar 30, 7:50AM CDT
KMI: 42.07 (+0.80), ACT: 304.76 (+1.20), JAH: 53.45 (+0.86), WBK: 30.26 (-0.09), CNQ: 30.83 (+0.10), DISH: 70.78 (+0.15), SU: 29.20 (+0.09), HCA: 76.17 (+0.10), GS: 191.02 (+2.96), JPM: 60.96 (+1.41), BAX: 68.76 (+0.21), RY: 59.35 (-0.30), TEVA: 62.52 (+0.54), SNY: 50.24 (+0.27), Y: 490.00 (+6.47), ECL: 114.79 (+0.55)
Which 4 Big Drugmakers Have Rising Estimates?
at Investor's Business Daily - Fri Mar 27, 12:16PM CDT
Drugmaker shares have been plunging this week, but the recent sell-off shouldn't necessarily be taken as an indicator that these stocks are doing poorly. Today's Screen of the Day features Leaders with Rising Estimates -- stocks with rising earnings...
LCI: 67.86 (+2.35), BIIB: 431.62 (+1.75), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40)
Has Orexigen Delivered A Death Knell To Vivus?
Spencer Osborne - at Seeking Alpha - Fri Mar 27, 9:37AM CDT
OREX: 7.75 (+0.21), ACT: 304.76 (+1.20), VVUS: 2.52 (-0.05)
Leon Cooperman's Firm Is Under Investigation and This Is Where He Is Investing His Money
at The Street - Fri Mar 27, 7:23AM CDT
Investigators looking into Leon Cooperman's Omega Advisors have quite a bit to wade through -- the billionaire has upwards of 90 securities in his public equity portfolio alone.
ACT: 304.76 (+1.20), RIG: 14.71 (+0.22), ATLS: 6.26 (+0.08), S: 4.75 (+0.03), HAL: 43.82 (+0.56), NAO: 9.10 (+0.25), LINE: 11.30 (-0.27), AIG: 54.68 (+0.65), SIRI: 3.87 (+0.02), NAVI: 20.08 (-0.08), APC: 83.85 (+1.66)
Top Large Cap Stocks That Investors Can Buy Now
Todd Campbell - at Seeking Alpha - Thu Mar 26, 2:20AM CDT
ASH: 128.71 (+1.18), OCR: 77.85 (+1.05), ACT: 304.76 (+1.20), BDX: 145.64 (+1.05), F: 16.16 (+0.18), CAH: 90.80 (+0.71), PSA: 199.19 (+1.71), SLG: 129.55 (+1.81), AON: 98.10 (+2.23), AET: 108.57 (+1.17), VTR: 73.65 (+1.33), CDW: 37.75 (-0.07), ANTM: 156.85 (+0.58), APH: 58.77 (+1.13), Q: 68.00 (+0.74), FL: 63.61 (+1.76), HSIC: 140.84 (+2.04), APD: 153.80 (+1.05), HAS: 62.57 (+1.54), ABT: 47.08 (+0.30), BCR: 169.37 (+1.66), HCN: 78.71 (+0.93), ORLY: 219.38 (+3.96), MCHP: 49.89 (+0.68), MYL: 60.00 (-1.63), DIS: 106.12 (+0.64), NXPI: 102.43 (+2.51), GLW: 23.24 (+0.50), MAR: 81.50 (+0.68), BA: 152.70 (+3.85), WAT: 124.94 (+0.83), ASML: 103.12 (+1.26), NVDA: 21.47 (+0.09), LVLT: 54.47 (+0.52), CTAS: 82.74 (+0.36), PLL: 101.63 (+1.14), AZO: 689.38 (+8.04), EQIX: 234.22 (+4.49), AVB: 176.15 (+2.03), SUNE: 24.19 (-0.17), TDG: 219.83 (+1.96), BEAV: 63.99 (+1.85), SHW: 284.24 (+2.56), FSL: 41.48 (+0.77), CRM: 66.85 (+0.30)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 157.27 (+1.47), BIIB: 431.62 (+1.75), IHF: 134.13 (+1.61), ACT: 304.76 (+1.20), VRX: 201.38 (+3.54), MRK: 58.34 (+0.59), SHPG: 241.98 (+1.01), PFE: 35.00 (+0.47), PTH: 61.68 (+1.07), XHS: 124.93 (+0.87), SLXP: 172.65 (+0.05), ABBV: 58.24 (+0.59)
Technical Analysis on Pharma Equities -- Zoetis, Horizon Pharma, Valeant Pharma Intl., Actavis, and Medicines
PR Newswire - Wed Mar 25, 8:57AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ZTS: 46.92 (+0.70), ACT: 304.76 (+1.20), VRX: 201.38 (+3.54), MDCO: 28.36 (-0.24), HZNP: 25.77 (+3.96), VRX.TO: 256.67 (+9.24)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ACT: 304.76 (+1.20), AIRM: 46.75 (-0.27), CENT: 10.08 (+0.04), AEZS: 0.53 (unch), AAPL: 126.37 (+3.12)
Trevena's Q4 2014 Results Conference Call - What We Learned
Scrying Biotech - at Seeking Alpha - Mon Mar 23, 12:14PM CDT
TRVN: 6.64 (-0.33), ACT: 304.76 (+1.20)
5 Rocket Stocks That Are Ready for Blastoff
at The Street - Mon Mar 23, 7:21AM CDT
These stocks have both short-term gain catalysts and longer-term growth potential.
ACT: 304.76 (+1.20), RAX: 52.38 (+0.42), ADI: 64.81 (+5.97), FL: 63.61 (+1.76), HOT: 84.33 (-0.90)
Vivus: Qsymia Sales Slip, Company Needs To Shift Into Gear
Spencer Osborne - at Seeking Alpha - Mon Mar 23, 5:51AM CDT
OREX: 7.75 (+0.21), ACT: 304.76 (+1.20), VVUS: 2.52 (-0.05), ARNA: 4.48 (+0.15)
Drug Stocks Are Hot: Meet The 5 Best On The IBD 50
at Investor's Business Daily - Sat Mar 21, 7:02AM CDT
Today's IBD 50 roundup features five top drugmakers that have been making headlines. Even though they've all now extended past buying range, they may yet form new bases, and investors won't want to be late to blink-and-you'll-miss-it key price...
ENDP: 91.53 (+1.49), BIIB: 431.62 (+1.75), VRX: 201.38 (+3.54), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40), SLXP: 172.65 (+0.05)
Is There Any Potential Left In Horizon Pharma Stock?
Max Grigoryev - at Seeking Alpha - Fri Mar 20, 1:55PM CDT
JNJ: 101.55 (+1.21), ACT: 304.76 (+1.20), PFE: 35.00 (+0.47), AZN: 69.94 (-0.13), HZNP: 25.77 (+3.96), MYL: 60.00 (-1.63), TEVA: 62.52 (+0.54)
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene
at The Street - Fri Mar 20, 6:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BIIB: 431.62 (+1.75), ACT: 304.76 (+1.20), OVAS: 38.18 (-5.29), RGLS: 17.26 (+0.44), CTIC: 1.87 (+0.06), CELG: 120.02 (+1.34), BLCM: 22.65 (+0.19), GILD: 100.69 (-0.31), KITE: 59.98 (+0.20), MRK: 58.34 (+0.59), RCPT: 160.05 (+12.62), JUNO: 60.66 (+4.06), NVS: 101.31 (+0.91)
AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 3:20PM CDT
AstraZeneca's (AZN) respiratory candidate, PT003, being developed for the treatment of chronic obstructive pulmonary disease, is found positive in late-stage PINNACLE studies.
ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40), AZN: 69.94 (-0.13), GSK: 47.20 (+0.18)
Global Parenteral Nutrition Industry
PR Newswire - Wed Mar 18, 3:51PM CDT
This report analyzes the worldwide markets for Parenteral Nutrition in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -
ACT: 304.76 (+1.20)
Actavis' pending acquisition of Allergan approved by European Commission
M2 - Wed Mar 18, 6:41AM CDT
Pharmaceutical company Actavis (NYSE:ACT) reported on Tuesday that it has received clearance from the European Commission for its pending acquisition of Allergan (NYSE:AGN).
AGN: 240.22 (+2.88), ACT: 304.76 (+1.20)
(0)
(0)
